1036388-83-6

Basic information

• Product Name: 6-bromo-2-fluoro-3-nitrobenzoic acid
• Synonyms: 6-bromo-2-fluoro-3-nitrobenzoic acid
• CAS NO: 1036388-83-6
• Molecular Weight: 264.008
• Mol File: 1036388-83-6.mol

Chemical Properties

• CAS DataBase Reference: 6-bromo-2-fluoro-3-nitrobenzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 6-bromo-2-fluoro-3-nitrobenzoic acid(1036388-83-6)
• EPA Substance Registry System: 6-bromo-2-fluoro-3-nitrobenzoic acid(1036388-83-6)

Safety Data

• Hazardous Substances Data: 1036388-83-6(Hazardous Substances Data)

Upstream product

• 2252-37-1 2-bromo-6-fluorobenzoic acid 
• 124-38-9 carbon dioxide 
• 321-23-3 4-bromo-2-fluoronitrobenzene 

Downstream Products

• 1036388-85-8 3-amino-2-cyano-6-fluorobenzoate methyl ester 
• 1036388-87-0 C₉H₇FN₂O₂ 
• 1036389-22-6 C₁₈H₁₇FN₂O₅ 
• 1036389-20-4 6-amino-7-fluoroisoindolin-1-one 

Relevant articles and documents

PROTEIN KINASE INHIBITORS FOR PROMOTING LIVER REGENERATION OR REDUCING OR PREVENTING HEPATOCYTE DEATH

The invention relates to compounds of formula (I) which are inhibitors of MKK4 (mitogen-activated protein kinase kinase 4) and their use in promoting liver regeneration or reducing or preventing hepatocyte death. The compounds selectively inhibit protein kinase MKK4 over protein kinases JNK and MKK7. (I), wherein R x, R y , R z and R zz are selected from: a) R x and R y are F and R z and R zz are H; b) R x, R y and R zz are independently halogen and R z is H; c) R x R z and R zz are independently halogen and R y is H; and d) R x R y and R z are independently halogen and R zz is H

Discovery of Phenylglycine Lactams as Potent Neutral Factor VIIa Inhibitors

Inhibitors of Factor VIIa (FVIIa), a serine protease in the clotting cascade, have shown strong antithrombotic efficacy in preclinical thrombosis models with minimal bleeding liabilities. Discovery of potent, orally active FVIIa inhibitors has been largely unsuccessful because known chemotypes have required a highly basic group in the S1 binding pocket for high affinity. A recently reported fragment screening effort resulted in the discovery of a neutral heterocycle, 7-chloro-3,4-dihydroisoquinolin-1(2H)-one, that binds in the S1 pocket of FVIIa and can be incorporated into a phenylglycine FVIIa inhibitor. Optimization of this P1 binding group led to the first series of neutral, permeable FVIIa inhibitors with low nanomolar potency.

BICYCLIC LACTAM FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS

The present invention provides novel bicyclic lactams derivatives, and analogues thereof, of Formula (I): or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein the variables A, B, C, W, Y, Z1, Z2, Z3, Z4, R8, and R9 are as defined herein. These compounds are selective inhibitors of factor VIIa which can be used as medicaments.